Bristol Myers Squibb (NYSE:BMY) is a top name in healthcare, with a market cap of around $125 billion today. But over the past five years, the stock has generated returns totaling just 6% and has been a fairly lackluster investment. By comparison, the S&P 500 has generated returns totaling nearly 70% over that same time frame. The market has been fairly bearish on Bristol Myers due to question marks about its future growth prospects, which has resulted in the stock trading at an incredibly low valuation today, and its yield being fairly high. Is it a bargain buy, or is this just a value trap that investors are better off steering clear of?
CryptoAlerta — análise de criptomoedas e mercado em tempo real